Catalyst Financial Partners LLC Has $325,000 Position in Boston Scientific Co. (NYSE:BSX)

Catalyst Financial Partners LLC raised its position in Boston Scientific Co. (NYSE:BSX) by 5.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,614 shares of the medical equipment provider’s stock after acquiring an additional 270 shares during the quarter. Catalyst Financial Partners LLC’s holdings in Boston Scientific were worth $325,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. lifted its stake in shares of Boston Scientific by 25.9% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 42,606 shares of the medical equipment provider’s stock worth $2,250,000 after buying an additional 8,766 shares during the last quarter. Mackenzie Financial Corp lifted its stake in shares of Boston Scientific by 15.8% during the 3rd quarter. Mackenzie Financial Corp now owns 429,320 shares of the medical equipment provider’s stock worth $22,127,000 after buying an additional 58,735 shares during the last quarter. Brighton Jones LLC lifted its stake in shares of Boston Scientific by 5.4% during the 3rd quarter. Brighton Jones LLC now owns 3,999 shares of the medical equipment provider’s stock worth $211,000 after buying an additional 205 shares during the last quarter. NBT Bank N A NY acquired a new stake in shares of Boston Scientific during the 3rd quarter worth about $253,000. Finally, Advisor Partners II LLC lifted its stake in shares of Boston Scientific by 4.9% during the 3rd quarter. Advisor Partners II LLC now owns 50,304 shares of the medical equipment provider’s stock worth $2,656,000 after buying an additional 2,342 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on BSX shares. Deutsche Bank Aktiengesellschaft raised their price target on shares of Boston Scientific from $63.00 to $73.00 and gave the stock a “hold” rating in a research report on Thursday, April 25th. Mizuho raised their price target on shares of Boston Scientific from $80.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. Evercore ISI raised their price target on shares of Boston Scientific from $72.00 to $78.00 and gave the stock an “outperform” rating in a research report on Thursday, April 25th. Royal Bank of Canada raised their price target on shares of Boston Scientific from $78.00 to $82.00 and gave the stock an “outperform” rating in a research report on Thursday, April 25th. Finally, UBS Group raised their price target on shares of Boston Scientific from $74.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $75.09.

Insider Activity at Boston Scientific

In related news, Director Charles J. Dockendorff sold 3,946 shares of Boston Scientific stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $72.70, for a total transaction of $286,874.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CFO Daniel J. Brennan sold 13,662 shares of Boston Scientific stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total transaction of $899,779.32. Following the sale, the chief financial officer now directly owns 271,542 shares in the company, valued at approximately $17,883,756.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Charles J. Dockendorff sold 3,946 shares of Boston Scientific stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $72.70, for a total transaction of $286,874.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 82,330 shares of company stock valued at $5,682,434. 0.50% of the stock is owned by insiders.

Boston Scientific Price Performance

Shares of Boston Scientific stock traded down $0.71 during midday trading on Wednesday, hitting $72.72. 5,036,563 shares of the company traded hands, compared to its average volume of 6,595,854. The stock has a market cap of $106.69 billion, a price-to-earnings ratio of 61.11, a PEG ratio of 2.51 and a beta of 0.77. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66. The firm’s fifty day moving average price is $68.68 and its 200-day moving average price is $61.74. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $74.39.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.